


Result No.	Query %			Length	DB	ID	Description
	Score	Match					
1	4880	99.3	919	18	AAWL4783	Androgen receptor.	
2	4880	99.3	919	21	AAV78914	Human androgen rec	
3	4872	99.2	919	20	AAAP93109	Human androgen rec	
4	4838.5	98.5	918	20	AAV33491	Human androgen rec	
5	4827.5	98.3	918	12	AAV12223	Human androgen rec	
6	4814	98.0	919	10	AAAP90396	Human androgen rec	
7	4201.5	85.5	902	10	AAAP91006	Rat androgen recep	
8	4200.5	85.5	902	10	AAAP93110	Rat androgen recep	
9	4187.5	85.3	902	12	AAV12224	Rat androgen recep	
10	2429	49.5	452	20	AAAT21627	Ligand binding dom	
11	1459	29.7	630	12	AAAL2230	TrpE/androgen rece	

XX	AAWI4783	AAWI4783 standard; Protein; 919 AA.
XX	AC	AAWI4783;
XX	DT	22-JUN-1997 (first entry)
XX	DE	Androgen receptor.
XX	KW	Androgen receptor; acidic fibroblast growth factor; aFGF;
XX	KW	antisense; benign prostatic hyperplasia; prostate cancer; therapy.
XX	OS	Homo sapiens.
XX	PN	WO9711170-A1.
XX	PD	27-MAR-1997
XX	PF	20-SEP-1996; 96WO-US15081.
XX	PP	20-SEP-1995; 95US-0004018.
XX	PPA	(WORC-) WORCESTER FOUND BIOMEDICAL RES.
XX	PI	namecnik PA.
XX	DR	WPI; 1997-202879/18.
XX	DR	N-PSDB; AAT63407.
XX	PT	Oligonucleotide(s) antisense to human androgen receptor and acidic
XX	PT	FGF genes - used to inhibit gene expression, for the treatment of
XX	PT	benign prostatic hyperplasia

841 ELDRIACKRNPTSCSRFFYQLTKLLDSVOPHAEHQLHFTDLKSHMVSVDPEMMA 900
837 eldriackrnptscsrffyltkllsdvqpiarelhqlftdlkshmvsvdfpemma 896

901 EIISVQVPKILSGKVKPIYFHTQ 923
897 elisvqvpkilsgkvkpiyfhtq 919

RESULT 2
AAV78914
ID AAV78914 standard; protein; 919 AA.
XX AAV78914;
XX
DT 23-MAY-2000 (first entry)
XX
DE Human androgen receptor (AR) amino acid sequence.
XX
KW Androgen receptor; AR: androgen-independent activation; inhibitor;
KW cancer; benign prostatic hyperplasia; hirsutism; androgenic alopecia;
KW acne; breast cancer; Kennedy disease; prostate cancer.
XX
OS Homo sapiens.
XX
PN WO200001813-A2.
XX
PD 13-JAN-2000.
XX
PF 30-JUN-1999; 99WO-CA00604.
XX
PR 30-JUN-1998; 98US-0091871.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Sadar MD, Bruchovsky N, Gout PW, Snoek R, Mawji NR;
XX WPI; 2000-182113/16.
XX
DR Novel non-androgen ligand binding peptides for inhibiting
PT androgen-independent activation of androgen receptor, used for
PT screening compounds and for treatment of androgen-mediated diseases
PT such as prostate cancer
XX
PS Disclosure; Page 7; 32pp; English.



This sequence represents the human androgen receptor (AR) amino acid sequence. The invention relates to a fragment of the AR corresponding to amino acids 234-391 (see AAV78913). The fragment mediates androgen-independent activation of the AR. The androgen receptor acts as a transcription factor, regulating the expression of certain androgen-responsive genes. Interaction of the AR with the protein kinase A signal transduction pathway involves interaction with the androgen independent region. The AR fragment and peptides derived from it can be used as agents for inhibiting androgen independent activation of the androgen receptor, as activation domains, and as a tool for screening for compounds which affect androgen-independent activation of the AR. The peptides, when used in combination with androgen deprivation, effectively limit androgen mediated disease progression. These diseases include cancer, benign prostatic hyperplasia, hirsutism, androgenic alopecia, acne, breast cancer, Kennedy disease, and especially prostate cancer. The peptides and nucleic acids encoding them, are especially used for the treatment of androgen-mediated diseases, especially prostate tumours in patients deprived of androgen.

Query Match 99.3%; Score 4880; DB 21; Length 919;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 919; Conservative 0; Mismatches 0; Indels 4; Gaps 1;
Qy 1 MEVQLGLGRVYPRPSKTYRGAFQNLFSQVREVIONFGRHPEAASAPGASILLVQQQ 60

PS Disclosure; Page 22-28; 51pp; English.
XX Human androgen receptor (AAW14783) binds testosterone and, acting at the transcriptional level, regulates the growth of normal prostatic cells. Antisense oligonucleotides (see also AAT63200, AAT63404-05) based on an androgen receptor cDNA clone (see also AAT63407) can be used to prevent androgen receptor gene expression, thereby inhibiting the growth or survival of prostatic cells for the treatment of benign prostatic hyperplasia and prostate cancer.
XX
SQ Sequence 919 AA;
Query Match 99.3%; Score 4880; DB 18; Length 919;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 919; Conservative 0; Mismatches 0; Indels 4; Gaps 1;
Qy 1 MEVQLGLGRVYPRPSKTYRGAFQNLFSQVREVIONFGRHPEAASAPGASILLVQQQ 60
Db 1 mevqlglgrvyrprrpsktyrgafqnlfsqvreviagnpgrthpeasaapggasillv--- 57
Qy 61 QQQQQQQQQQQQQQQQQQQQQSPROQQQQQGGEDGSPQAHRRGPTGYLVLDDEEQPSQ 120
Db 58 -qqqqqqqqqqqqqqqqqqqqqspqqqqqqqqedgspqahrrgptgylvlddeeqpsq 116
Qy 121 POSALECHPERGCVPEPAAVAASKGLPQPLPAPDEDDSAAPSTLSLLGPTFFGLSSCS 180
Db 117 pqsalechpergcvpepaaavaaskglpqpapddedsaapstlsllgptffglsscs 176
Qy 181 ADLKDILFASFMQLQQ 240
Db 177 adldkdlfasmqlqq 236
Qy 241 LCKAVSVSMGLGVEALEHLSPEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLDD 300
Db 237 lckavsvsmglgvealehlspeqlrgdcmyapllgvppavrpptcaplaeckgsllds 296
Qy 301 AKKSTEDRAYSPFGKGYTKLEGESLCSGSAAGSSGTLELPSTLSLYKSGALDEAAA 360
Db 297 agkstedaeyspfgkgytklegeslcsgsaaagssgtlelpstlslyksгалdeaaa 356
Qy 361 YQSRDYNPFLALAGPPPPPPPPHPRARIKLENPLDYGSANAAAAQCRYGDLASLHAG 420
Db 357 yqsrdynpflalagpppppppphprariklenpldygsanaaaaqcrygdlaslhag 416
Qy 421 AAGPGSGSPSAASSWHITFAEQLYPCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGA 480
Db 417 aagpgsgspsaasswhitfaeqlypcgggggggggggggggggggggggggggga 476
Qy 481 VAPYGTREPQGLAGESDFTAPDVMYPGMYSRYPYPSPTCVKSEMGPMWDSYSGPYGD 540
Db 477 vapygytrppqglaggesdftapdvmypgmysrypypsptcvksempgmwdsysgpygd 536
Qy 541 MRLETARDHVLPIIDYFPFKTCLICGDEASGCHYGALTCGSKVFFKRAEGKQYICA 600
Db 537 mrletardhvlpidyfpfkctclicgdeasgchygaltcgskvffkraegkkyica 596
Qy 601 SRNDCTIDFRNKNCSRLKCYEAGMTLGARKLKLGNLKLQEGEASSTTSPTET 660
Db 597 srndctidfrnknscrlkcyeamtltgarklklgnlklqeegeassttspteett 656
Qy 661 QKLTSHIEGYECQPIFLNLEAIEPGVVCAGHDNNQPSFAALLSSLNELGERQLVHV 720
Db 657 qkltshiegyecqpfllnleaiiepgvvcaghdnnqpsfaallssnelgerqlvhv 716
Qy 721 KWAKALPGFRLHVDQMAVIQYVSMGLMVFMGWSRFTNVNRMILYFAPDLVFNRYMH 780
Db 717 kwakalpgfrrlhvdqmvaiqysmglmvmfwgwsrftnvnsrmilyfapdlvfnrymh 776
Qy 781 KSRMYSCVWRHLSDQFGLQTTPOEFLCMKALLLSIIPDGLKNOKFFOELRMNYIK 840
Db 777 ksrmyscvwrhlsgdfglqttptoeelcmkalllsiipdglknokffdelrmnyik 836

```

Db 1 mevqlglgrvyprrpsktyrgafnlfqsvrevignprrpheaasaaappgaslll--- 57
QY 61 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 120
Db 58 -qqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq 116
QY 121 QSALCHPERGCVPEPAAVAAASKGLPOOLPAPDEDDSAAPSTLSLLGPTFFGLSSCS 180
Db 117 pqsalechpergcvpepaaavaaskglpqgppapddeddaapstlsllgptfplsscs 176
QY 181 ADUKDILSEASTMQLLOQQQQQFAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAAKE 240
Db 177 adlkdlileastmqllqqqqqeaavsegsgrareasgaptsskdnlylggtstisdnake 236
QY 241 LKAVSVSMGLGVEALEHLSPEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLDDDS 300
Db 237 lckavsvsmglgvealehlspeqlrgdcmyapllgvppavrtpcaplaeckgslldds 296
QY 301 AGKSTEDTAESYSPFKGGYTKGLESGSLGCSGSAAGSGTLELPTLSLYKSGALDEAAA 360
Db 297 agkstedtaesyfpkgytkglesgslgcsgsaaagsgtllpeltstlslyks9aldgaaa 356
QY 361 YOSRDYNNPLALAGPPPPPPPPHARIKLENPLDYGSAAAAAOCRYGDLASLHGAG 420
Db 357 ygsrdyynfplalagpppppppphphariklenpldygsawaaaaaacyrgdlaslhag 416
QY 421 AAGPGSGPSAAASSWHTLFTAEQOLYPCGGGGGGGGGGGGGGGGGGGGGGGGGAGA 480
Db 417 aagpgsgpsaaaswhltftaeegqlypgcgggggggggggggggggggggggggaga 476
QY 481 VAPYGYTRPPQGLAGQESDFTAPDVMVPGMVSRVPSPPTCVKSEMPWMDSYSGPYGD 540
Db 477 vapygytrppqglagqesdftapdvmvpggmvsrvpysptcvksengpwmmdsygygd 536
QY 541 MRLETARDHVLPIIDYFPPOKTCILICGDEASGCHYGALTCGSKVFPKRAEKGKYLCA 600
Db 537 mletardhvlpidyfpqoktcilicgdeasgchygaltcgskvfkraeagkqylca 596
QY 601 SRNDCTIDKFRKNCPSRLKCYEAGMTLGARKLKLGNLKLQEEGEASSTSPTEET 660
Db 597 srndctidkfrkncpsrlkcyeamtlgarklklgnlklqeegeasstspceet 656
QY 661 OKLTVSHTEGECQPIFLNVLEATEPGVWCAGHDNNOPDSFAALLSLNELGRQLVHV 720
Db 657 qkltvshlegecqpiflnvleatepgvwcaghdnngpdsfaallsslnelgerqlvhv 716
QY 721 KWAKALPGRNRLHVDQMAVITQYSWMGLMVFAMGWSFTNVNSRMLYFAPDLVFNRYMH 780
Db 717 kwakalpgrnrlhvdqmvayiqyswmglmvfmgwsftnvnrmlyfapdlvfnrymh 776
QY 781 KSMYSQCVRMHLSQEFGLQITPQEFCLMKALLFSIIPVDGLKNQKFFDELRMNYIK 840
Db 777 ksmysqcvrmhlsqefglqitpqefclmkallfslipvdglknqkffdelrmnyik 836
QY 841 ELDRITACKRNKPTSCRRRYVQLTKLSDVQPTARELHQTFDLLIKSHMWSDPEMMA 900
Db 837 eldriackrnkptscrrryvqltklksdvqptarelhqtfdllikshmwsvdpemma 896
QY 901 EIIISVQPKILSGKVKPIYFHTQ 923
Db 897 elisvqpkilsgkvkpiyfhtq 919

```

RESULT 3
 AAP93109
 ID AAP93109 standard; protein; 919 AA.
 XX
 AC AAP93109;
 XX
 XX 19-MAR-1990 (first entry)
 DT
 XX Human androgen receptor.
 DE

XX KW Human androgen receptor; ployclonal antibody; cancer.
 XX OS Homo sapiens.
 XX PN WO8909791-A.
 XX RD 19-OCT-1989.
 XX PF 13-APR-1989; 89WO-US01548.
 XX PR 14-APR-1988; 88US-0182646.
 XX PA (UYNC-) UNIVERSITY OF NORTH CAROLINA.
 XX PI French FS, Wilson EM, Joseph DR, Lubahn DB;
 XX N-PSDB; AAN91772.
 XX WPI: 1989-324206/44.
 XX DNA encoding androgen receptor protein - useful for transforming eukaryotic hosts for protein expression and subsequent antibody prodn.
 XX PS Disclosure; Fig. 4; 41pp; English.
 XX CC Androgen receptor protein (AR) is used to produce mono- or poly-clonal antibodies. These are used for the detection and quantification of AR in the presence of endogenous androgen, as androgen will not interfere with binding. They may be used in assays to determine and quantify cellular distribution of AR in tumour tissue, and are esp. useful for evaluating prostate cancers to determine responsiveness to androgen withdrawal therapy.
 XX SQ Sequence 919 AA;

Query Match 99.2%; Score 4872; DB 10; Length 919;
 Best Local Similarity 99.5%; Pred. No. 0;
 Matches 918; Conservative 0; Mismatches 1; Indels 4; Gaps 1;
 QY 1 MEVOLGLGRVYPRPSPKTYRGAFONLFQSVREVIGNPGRHPEAAASAPGASLLTQQQ 60
 Db 1 mevqlglgrvyprrpsktyrgafnlfqsvrevignprrpheaasaaappgaslll--- 57
 QY 61 QQQ 120
 Db 58 -qq 116
 QY 121 QSALCHPERGCVPEPAAVAAASKGLPOOLPAPDEDDSAAPSTLSLLGPTFFGLSSCS 180
 Db 117 pqsalechpergcvpepaaavaaskglpqgppapddeddaapstlsllgptfplsscs 176
 QY 181 ADUKDILSEASTMQLLOQQQQQFAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAAKE 240
 Db 177 adlkdlileastmqllqqqqqeaavsegsgrareasgaptsskdnlylggtstisdnake 236
 QY 241 LKAVSVSMGLGVEALEHLSPEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLDDDS 300
 Db 237 lckavsvsmglgvealehlspeqlrgdcmyapllgvppavrtpcaplaeckgslldds 296
 QY 301 AGKSTEDTAESYSPFKGGYTKGLESGSLGCSGSAAGSGTLELPTLSLYKSGALDEAAA 360
 Db 297 agkstedtaesyfpkgytkglesgslgcsgsaaagsgtllpeltstlslyks9aldgaaa 356
 QY 361 YOSRDYNNPLALAGPPPPPPPPHARIKLENPLDYGSAAAAAOCRYGDLASLHGAG 420
 Db 357 ygsrdyynfplalagpppppppphphariklenpldygsawaaaaaacyrgdlaslhag 416
 QY 421 AAGPGSGPSAAASSWHTLFTAEQOLYPCGGGGGGGGGGGGGGGGGGGGGGGGGAGA 480
 Db 417 aagpgsgpsaaaswhltftaeegqlypgcgggggggggggggggggggggggggaga 476
 QY 481 VAPYGYTRPPQGLAGQESDFTAPDVMVPGMVSRVPSPPTCVKSEMPWMDSYSGPYGD 540

Db 477 vapygytrpqqlagqesdftapdvvyppgmvsvrpypsptcvksemgpmwmdsyspygd 536
Qy 541 MRLETARDHVLPIIDYPPPOKTCICGDEASGCHYGALTCGCKVFVKRAAEKQKYLCA 600
Db 537 mrletardhvlpidypppqtclcgdeasgchygaltcgscvfkfakraegkqylca 596
Qy 601 SRNDCTIDKFRKNCPSRLKCYEAGMTLGARKLKLGNLKLQEGEASSTTSPTEET 660
Db 597 srndctidkfrkncpsrclrkcyeamtlgarklklgnlklqeegeassttspteet 656
Qy 661 QKLTVSHIEGVECOPIFLNLEAIEPGVVCAGHDNPNQDSFAALLSSNLGELGERQLVHV 720
Db 657 qkltvshiegvecaiflnvlealepvcaghdnnpqdsfaallssnlgelgerqlvhv 716
Qy 721 KWALPGFERNLHVDDQMAVTOYSWMGLMFMVAMGWRFTNVNSRMLYFADPLVFNERYMH 780
Db 717 kwkalpgfarnlhvddgmavtqyswmglmfmvfwgwrftnvnsmlyfapdlvfnerymh 776
Qy 781 KSRMYSQCVRMRLHSQEGWLOITPQEFCLMKALLLSIIPVDGLKKNQKFFDELRMNYIK 840
Db 777 ksrmysqcvrmrlhsqefgwloitpqefclmkalllsiipvdglkknqkffdelrmnyik 836
Qy 841 ELDRILIAKRNKPTSCSRFVQLKLLDSVOPIARELHQFTEDLLIKSHMVSVDFPEMMA 900
Db 837 eldrilackrnkptscsrfrvqlklldsvoqiarelhqftedllikshmvsvdfpemma 896
Qy 901 ELISVQPKILSGVKPIYFHTQ 923
Db 897 elisvqpkilsgvkpiyfhtq 919
RESULT 4
ID AAY33491 standard; Protein; 918 AA.
XX AAY33491;
XX 19-JAN-2000 (first entry)
XX Human androgen receptor protein.
DE
DE
KW Proapoptotic; dependence domain; p75NTR; androgen receptor; DCC;
KW huntingtin polypeptide; Machado-Joseph disease; SCAL; SCA2; SCA6;
KW atrophin-1; cell death; apoptosis; Huntington's disease; head trauma;
KW Alzheimer's disease; Kennedy's disease; spinocerebellar ataxia; stroke;
KW dentatorubralidolusian atrophy; cell proliferation; cell survival;
KW neoplastic; malignant; autoimmune; fibrotic.
OS Homo sapiens.
XX
XX WO9945944-A1.
XX PN
XX PD 16-SEP-1999.
XX
XX 11-MAR-1999; 99WO-US05250.
XX
XX 12-MAR-1998; 98US-0041886.
XX
XX (BURN-) BURNHAM INST.
XX
XX Bredesen DE, Rabizadeh S;
XX PI
XX WPI; 1999-561617/47.
XX N-PSDB; AAZ23424.
XX
XX New proapoptotic dependence peptides, used to develop products for
XX treating, e.g. Alzheimer's disease -
XX
XX Disclosure; Page 90-93; 199pp; English.
XX
XX This invention describes novel pure proapoptotic dependence peptides
XX which comprise a sequence of an active dependence domain selected from
CC

CC dependence polypeptides consisting of p75NTR, androgen receptor, DCC,
CC huntingtin polypeptide, Machado-Joseph disease gene product, SCAL, SCA2,
CC SCA6 and atrophin-1 polypeptide. The proapoptotic peptides are capable
CC of inducing cell death and can be used to develop products to mediate or
CC inhibit apoptosis. The methods can be used for reducing the severity of
CC a proapoptotic dependence domain mediated pathological conditions e.g.
CC Huntington's disease, Alzheimer's disease, Kennedy's disease,
CC Spinocerebellar ataxias, dentatorubralidolusian atrophy,
CC Machado-Joseph disease, stroke or head trauma. They can also be used for
CC reducing the severity of a pathological condition mediated by upregulated
CC cell proliferation or cell survival e.g. neoplastic, malignant,
CC autoimmune or fibrotic conditions. This sequence represents a human
CC androgen receptor described in the method of the invention.
XX
XX Sequence 918 AA;
SQ
Query Match 98.5%; Score 4838.5; DB 20; Length 918;
Best Local Similarity 98.7%; Pred. No. 6.4e-318;
Matches 914; Conservative 0; Mismatches 1; Indels 11; Gaps 2;
Qy 1 MEVOLGLGRVYRPSPSKTYRGAFQNLFSQREVIONPGRIPEAASAPPASLILLQQQ 60
Db 1 mevqlglgrvyrpssktyrgafqnlfsqrevionpgripheaaasappgaslill--- 57
Qy 61 QQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQQGGEDGSPQAHRRGPTGYLVLDDEQFSQ 120
Db 58 ----qqqqqqqqqqqqqqqqqqqqprqqqqqqggsqahrrgptgylvlddeeqbsq 112
Qy 121 PQSALECHPERGCVPEPGAAVAASKGLPQOLPAPDEDDSAAPSTLSLLGPTFPGLSGCS 180
Db 113 pgsalechpergcvpepgaavaaskglpqolpappeddosaapstlsllgptfpglsfcs 172
Qy 181 ADLKDLILSEASTMOLLQOQQQQQQQQQQETSPRQQQQQQQGGEDGSPQAHRRGPTGYLVLDDEQFSQ 240
Db 173 adlkdlilseastmqlllqqqqqqqqqqqqqqqqqqqqsgsgrareasgaptskdnylggttsidnake 232
Qy 241 LCKAVSVSMGLGVEALEHLSLPGQLRGDCMYAPLGVPPVAVRPTPCAPLAECKGSLDDSD 300
Db 233 lckavsvsmglgvealehlspsgeqlrgdcmypavrpvcaplaecksgldds 292
Qy 301 AGKSTEDTAESYSPFKGYTKGLESGISGCSAAAGSGTLEPLSTLSLYKSGALDEAAA 360
Db 293 agkstedtaesydfkgytkglegeslgcsaaagsgtclepstslyksgaldea 352
Qy 361 YQSRDYNNFLALAGPPPPPPHARIKLENPLDYSAWAAAAOQCRYGDIASLHGAG 420
Db 353 yqsrdyynflalagppppppharklenpldysawaaaaaqcrygdiaslhgsq 412
Qy 421 AAGPGSGSPSAAAASSSWHTLFTABEGQLYGPC---GGGGGGGGGGGGGGGGGGGG 477
Db 413 aagpgsgspsaassswhtlftaeeqglypcggggggggggggggggggggggg 472
Qy 478 AGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGMWDSYSGP 537
Db 473 aeavapygytrppqglagqesdftapdvwyppgmvsvrpypsptcvksemgpmwdsysgp 532
Qy 538 YGDMRLETARDHVLPIIDYYPPOKTCICGDEASGCHYGALTCGCKVFVKRAAEKQKY 597
Db 533 ygdmrletardhvlpidyypfpkqtclicgdeasgchygaltcgscvfkfakraekqky 592
Qy 598 LCASRNDCTIDKFRKNCPSRLKCYEAGMTLGARKLKLGNLKLQEGEASSTTSPTE 657
Db 593 lcasrndctidkfrkncpsrclrkcyeamtlgarklklgnlklqeegeassttspte 652
Qy 658 ETTOKLVSHIEGVECOPIFLNLEAIEPGVVCAGHDNPNQDSFAALLSSNLGELGERQLV 717
Db 653 ettoklvshiegvecpiflnvlealepvcaghdnnpqdsfaallssnlgelgerqlv 712
Qy 718 HVVKWAKALPGFERNLHVDDQMAVTOYSWMGLMFMVAMGWRFTNVNSRMLYFADPLVFN 777
Db 713 hvvkwalpgfarnlhvddgmavtqyswmglmfmvfwgwrftnvnsmlyfapdlvfn 772

QY 778 RMHKSRYMYSQVCRMRHLSQBFGLQITPOEFLCMKALLLSIIPVDGLKNOKFFDELRMN 837
 Db 773 rmhksrmysqcvrmrhlsgfqlwqltpqeflcmkalllsipvdglknqkffdelrmn 832
 QY 838 YIKELDRITACKRKNPTSCSRRYQITKLDSVQPIARELHQFTDLLIKSHMVSVDFFE 897
 Db 833 yikeldritackrknptscsrffyqitkildsvqpiarelhgtfdllikshmvsvdfpe 892
 QY 898 MMAEIIISVQVPKILSGVKPIYFHTQ 923
 Db 893 mmaeiisvqvpkilsqvkpiyftcq 918

RESULT 5
 AAR12223
 ID AAR12223 standard; Protein; 918 AA.
 AC AAR12223;
 DT 20-AUG-1991 (first entry)
 XX Human androgen receptor.
 DE hAR; DNA-binding protein; steroid hormone.
 KW hAR; DNA-binding protein; steroid hormone.
 XX Hemo sapiens.
 OS Hemo sapiens.
 FH Key Location/Qualifiers
 FT Domain 556..626
 FT /label= DNA-binding domain
 FT /note= "cysteine-rich"

W09107423-A.
 PD 30-MAY-1991.
 PF 19-SEP-1990; 90WO-US06015.
 PR 17-NOV-1989; 89US-0438775.

(ARCH-) ARCH DEV CORP.
 PI Liao S, Chang C;
 DR WPI-1991-178048/24.
 DR N-PSDB; AAQ12001.

Androgen receptor and TR2 DNA binding proteins - DNA sequences
 and antibodies for detection and quantification methods
 Claim 25; Fig 3; 79pp; English.

This sequence was deduced from a cDNA clone isolated by screening commercially available human testis and prostate lambda gt11 cDNA libraries. The sequence is very similar to that of rat AR and in the DNA-binding domain it is identical to that of rat AR DNA-binding domain. Homology comparisons with other known steroid receptors indicate that hAR is more closely related to glucocorticoid, mineralo-corticoid and progesterone receptors than to v-erb-A or to receptors for oestrogen, vitamin D and thyroid hormones.

Sequence 918 AA;

Query Match 98.38; Score 4827.5; DB 12; Length 918;
 Best Local Similarity 98.5%; Pred. No. 3.4e-317;
 Matches 912; Conservative 1; Mismatches 2; Indels 11; Gaps 2;

QY 1 MEVQLGLGRVYPRPSTKYRGAFONLFQSVREVQNCPRHPEAASAPPCASLLILQ 60
 Db 1 mevqlglgrvyrppstkyrgafnlfgsvrevlqnprrhpeasaappgasllilf 57
 QY 61 QQQ 120

Db 58 -----qq 112
 QY 121 PQSALECHPERGCVPEPCGAAYAAAKGLPQOLPAPDEDDSAAPSTLSLLGTFPGLSSCS 180
 Db 113 pqsalechpergcvpepgaavaaakglpqqlpapeddeddsapstlsllgtpfpglsscs 172
 QY 181 ADLKDILSEASTMQLLOQQOQAEAVSESSSGRAREASCAPTSSKNDNYLGTSTISDNAKE 240
 Db 173 adlkdilseastmqlloqqqaeavsegsgrareasagaptsskndnylgtstisdnake 232
 QY 241 LCKAVSVSMGLGVEALEHLSPEQIRGDCNTYAPILGVPPAVRPTCAPLAECCKGSLDDDS 300
 Db 233 lckavsvsmglgvealehlspeqirgdcmyapilgvppavrvptcaplaeckgslldds 292
 QY 301 AGKSTEDTAEYSPFKGGYTKLEGESLGCSSAAAGSGTLELPSTLSLYKSGALDEAAA 360
 Db 293 agkstedtaeyspfkgytklegeslgcsgsaaagsgtclepstlslyksgaldeaaa 352
 QY 361 YOSRDYNYFPLALAGPPPPPPPPHARIKLENP LDYGSAAWAAAACRYGDLASLHGAG 420
 Db 353 ygsrdyynfplalagppppppppharkleoplldygsawaaaacrygdiaslhag 412
 QY 421 AAGPGSGSPSAAASSWHTLFTAEQGOLYFPC---GGGGGGGGGGGGGGGGGGGGGG 477
 Db 413 aarpgspsaaasswhtlftaeegqlyfpcggggggggggggggggggggggggggg 472
 QY 478 AGAVAPYGYTRPQGLAGQESDFTAPDVWYPGMVSRVPYSPCTCVKSEMPWMDSYSGP 537
 Db 473 aeavapygytrppqglagqesdftapdvwpgmvsvrpypsptcvksemppwmdsysgp 532
 QY 538 YGDMRLETARDHVLPIDYFPPOKTCCLICGDEASGCHYGALTCGSCCKVFFKRAAEQKQY 597
 Db 533 ygdmrletardhvlpidyfpqkctclicgdeasgchygaltcgscckvffkraaeqkqy 592
 QY 598 LCASRNDCTIDKFRKNCPCRLKCYEAGMTLGARKLKLGNLKLQOEAGEASTTSPT 657
 Db 593 lcasrndctidkfrkncpcrkrkyeagmtlgarklklgnlklqoeageasttspte 652
 QY 658 ETQKLTIVSHIEGYEQIFLNVLAEIPEGVVCAGHDNNQPDFAALLSLSNELGERQLV 717
 Db 653 ettqkltvshiegyeqpiflnvlaeipgvvcaghdnnqpdffaallsnelgerqlv 712
 QY 718 HVYKWKALPGFERNLHVDDOMAVIOYSWGLMVFAMGWSFTNVNSRMLYFAPDLVNEY 777
 Db 713 hvkwkalpgfgrnlhvddomavieswnglmvfamgwrsftnvnrmlyfapdlvney 772
 QY 778 RMHKSRYMYSQVCRMRHLSQBFGLQITPOEFLCMKALLLSIIPVDGLKNOKFFDELRMN 837
 Db 773 rmhksrmysqcvrmrhlsgfqlwqltpqeflcmkalllsipvdglknqkffdelrmn 832
 QY 838 YIKELDRITACKRKNPTSCSRRYQITKLDSVQPIARELHQFTDLLIKSHMVSVDFFE 897
 Db 833 yikeldritackrknptscsrffyqitkildsvqpiarelhgtfdllikshmvsvdfpe 892
 QY 898 MMAEIIISVQVPKILSGVKPIYFHTQ 923
 Db 893 mmaeiisvqvpkilsqvkpiyftcq 918

RESULT 6
 AAR90996
 ID AAR90996 standard; protein; 919 AA.
 AC AAR90996;
 DT 28-FEB-1990 (first entry)
 XX Human androgen receptor DNA clone.
 DE Androgen receptor.
 KW Androgen receptor.
 OS Homo sapiens.

XX Key Location/Qualifiers
FH 1..919
FT /*tag= a
FT /product=98 kD polypeptide
FT 185..919
FT /*tag= b
FT /product=79 kD polypeptide
XX W08909223-A.
XX 05-OCT-1989.
XX 24-MAR-1989; 89WO-US01238.
XX 30-MAR-1988; 88US-0176107.
XX (ARCH-) ARCH DEVELOPMENT CORP.
XX Liao S, Chang C;
XX WPI: 1989-309501/42.
XX N-PSDB; AAN91577.
XX New DNA encoding new androgen receptor and TR2 polypeptide(s) - able to bind DNA, and derived antibodies, useful for receptor assay and purification.
XX Claim 8; Fig 3; 60pp; English.
XX The protein is used to raise antibodies for receptor assays and for affinity purification.
XX The 98 kD product starts at the first Met codon; the 79 kD product starts from the second.
XX Sequence 919 AA;
Query Match 98.0%; Score 4814; DB 10; Length 919;
Best Local Similarity 98.4%; Pred. No. 2.8e-316;
Matches 912; Conservable 0; Mismatches 3; Indels 12; Gaps 3;
QY 1 MEVQLGLGVYPRPSKTYRGAFQNLFSVREVIONPGPHPEAASAPPASILLILQQQ 60
DB 1 MEVQIGLGRVYPRPSKTYRGAFQNLFSVREVIONPGPHPEAASAPPASILLILQQQ 57
QY 61 QQQ 119
DB 58 -----GQQ 112
QY 120 QPQSALECHPERGCVPEPCAAVAASKGLPQQLPAPPDEDDSAAPSTLSLGLTPPLSSC 179
DB 113 qpqsalchpergcvpepcgaavaaskglpqqlpappdeddsapstlsilgtpplsscc 172
QY 180 SADLKDILSEASTMQLQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 239
DB 173 sadlkilseastmqlqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq 232
QY 240 ELCKAVSVSMGLGVEALEHLSPEQLRGDCMYAPILGVPPAVRPTPCAPLAECKSLIDD 299
DB 233 elckavsvsmglgvealehlspeqlrgdcmyapilgvppavrpaplaeckslidd 292
QY 300 SAKGSTEDTAEYSPFKGGVTKLEGESLGGSGAAGSGGTLELPSLTLKSGALDEAA 359
DB 293 sadgstedaeyspfkggvtklegeslggsgaagsggtlelpsltlksgaldea 352
QY 360 AYQSRDYNFPLALAGPPPPPPHPPHARIKLENPLDYGSAAAAAACRYGDLASLHGA 419
DB 353 aygsrdynfplalagpppppphphariklenpldygsawaaaaaqcrygdlaslgha 412
QY 420 GAAGPGSGPSAASSWHTLFAEEGQLYGPC---GGGGGGGGGGGGGGGGGGGGGGGG 476
DB 413 gaagpgsgpsaasswhtlftaeegqlygpcgpggggggggggggggggggggggggg 472

QY 477 EAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYSPCTCVKSEMGPMWDSYSG 536
DB 473 eaeavapygytrppqglagqesdftapdvwypggmvsrvpyspctcvksempgmwdsysg 532
QY 537 PYGDMRLLETARDHVLPIDYFPPOKTCCLICGDEASGCHYGALTCGSKCVFFKRAEGKQK 596
DB 533 pygdmrletardhvlpidyfpqkctclcgdeasgchygaltcgscckvffkraegkqk 592
QY 597 YLCASRNDCITDKFRKNCPCRLKCYEAGMTLCARLKKLGNLKLQEEGASSTTSPT 656
DB 593 ylcasrndctidkfrkncpcsrllrckyeagmtlgarklklgnlklqeegeassttspt 652
QY 657 EETOKLTVSHIEGECOPIFLNVLEATEPGVVCAGHDNNQPDSPALLSSINELGERQL 716
DB 653 eettokltvshiegecqipflnvleatepgvvcaghnnqpdspallssinelgerql 712
QY 717 VHVVKWAKALPGERNLHVDQMAVIOYSMMGLMVFAMGWRSETNVNSRMLFAPDLVNE 776
DB 713 vhvkwakalpgfrnlhvddqnaviqyswmglmvfamgwrsetnvnsrmlfapdlvine 772
QY 777 YRMHKSRYSCQVRMRHLSEEGWLOITPOEFLCMKALLLSIIPVDGLKNOKPFDELRM 836
DB 773 yrmhksrmysqcvrmrhlsegefwiqtpqeflcmkalllsiipvdglknokpfidelrm 832
QY 837 NYIKELDRIIACKRNKPTSCSRFFYQLTKLDSVOPIARELHQFTFDLLIKSHMVSVDPP 896
DB 833 nyikelldriiackrnkptscsrffyqltkltdsvopiarrelhbqftfdllikshmvsvdpp 892
QY 897 EMMAETISVOVKILSGKVKPIYFHTQ 923
DB 893 emmaetisvqvkilsgkvkpiyfhtq 919
RESULT 7
AAP91006
ID AAP91006 standard; protein; 902 AA.
XX AC AAP91006;
XX DT 28-FEB-1990 (first entry)
XX DE Rat androgen receptor DNA clone.
XX DE Androgen receptor; TR2 polypeptide; **TR-2**
XX KW Androgen receptor; TR2 polypeptide;
XX OS Rat.
XX FH Key Location/Qualifiers
FT Region 1..902
FT /*tag= a
FT /product=98 kD polypeptide
FT 170..902
FT Region /*tag= b
FT /product=79 kD polypeptide
XX PN W08909223-A.
XX DD 05-OCT-1989
XX PF 24-MAR-1989; 89WO-US01238.
XX PR 30-MAR-1988; 88US-0176107.
XX PA (ARCH-) ARCH DEVELOPMENT CORP.
XX PI Liao S, Chang C
XX DR WPI: 1989-309501/42.
XX DR N-PSDB; AAN91577.
XX PT New DNA encoding new androgen receptor and TR2 polypeptide(s) - able to bind DNA, and derived antibodies, useful for receptor assay and

PT purification.

PS Claim 8; Fig 3; 60pp; English.

XX The protein is used to raise antibodies for receptor assays and for
 CC affinity purification.
 CC The 98 kD product starts at the first Met codon; the 79 kD product
 CC starts from the second.
 XX
 XX Sequence 902 AA;

SQ

Query Match 85.5%; Score 4200.5; DB 10; Length 902;
 Best Local Similarity 84.6%; Pred. No. 5.6e-275;
 Matches 796; Conservative 36; Mismatches 52; Indels 57; Gaps 4;

QY 1 MEVOLGLGRVYPRPSPKTYRGAFQNLFGSVREVIONPGPRHPEAASAPPASLLLLQQQ 60
 Db 1 mevhlglgrvyrppsktyrgafqnlfgsvreaiqnpgrhpeaasiappgacl-----54
 QY 61 QQQ 119
 Db 55 -----qqrqetprrrrrqhpqdgspqahirgttgylaleeqgqs 96
 QY 120 QPQSALECHPERGCVPEFGAAVAASKGLPQQLPAPDEDDSAAPSTLSLLGPTFPGLSSC 179
 Db 97 qqgsaseghpesgcipegaatapgkglpqppappdgdasaapstlsllgptfpglssc 156
 QY 180 SADLKDILSEASTMOLL-----QQQQQEAIVSESSSGRAREAGAPTS 222
 Db 157 sadikdlilseagtmllqq 216
 QY 223 SKDNYLGTSITSDNAKELCAVSMGLVEALEHLSPEQLRGDCMYAPLLGVPVPAVR 282
 Db 217 skdsylggnstidsakelcavsmglvealehlspeqlrgdcmyasllgpppavr 276
 QY 283 PTPCAPLAECKSLDDSNAGKSTEDTAESFPKGYTKGLEGESLGCSGSAAGSSGTL 342
 Db 277 ptpcaplaecksliddegpkgteteaeyssfkgyakglegeslgcsseagsgtle 336
 QY 343 LPSTLSLYKSGALDEAAAYQRDYYNFFLALAGPPPPPPHARIKLENPLDYGSAWA 402
 Db 337 lpslslyksgavdeaaayqrdyynfflalsgpppppphpharikienpldygsawa 396
 QY 403 AAAACRYGDLASLHGAAGPAGSGSPSAAASSMHTLFTAEQGLXGCGCGGGGGGGG 462
 Db 397 aaaaacrygdlaslhgsvagpstspsatassswhlftaeeglygp-----445
 QY 463 GGGGGGGGGGGGGGAGAVAPYGVTRPPQGLAGQESDFTAPDVPYPGMVSVPSPPTC 522
 Db 446 ---ggggggsspsdagpavpygytrppqqlasqgdgsasevwyppgvvrpypspc 501
 QY 523 VKSEMGPMWDSYSGPYGDMRLTARDHVLPIIDYFFPPQKTCICGEASGCHYALTCSG 582
 Db 502 vksemgpmwnyspygdmrlstrdhvlpidyfppqktcltcgdeaschygaltcgs 561
 QY 583 CKVFKRAEGKQKYLCAASNDCHIDFRKNCPSCRLKCYEAGMTGLARKLKLGNLK 642
 Db 562 ckvfkraegkqkylcasndctidkfrknpcscrlkcyeamtglarklklgnlk 621
 QY 643 LQEEGEASSTTSPEETQKLTVSHIEGECOPTFLNVLAEALPGVVCAGHDNNQDPSFA 702
 Db 622 lqeegeasagtpedsqmntvshlegecqplfnvlealepgvvvcadhdnqpsfa 681
 QY 703 ALLSSNLGRLQVLHVVKWAKALPGFRLNLDVDDMAVIOYVSWGLMVMFAMGWRSTNVN 762
 Db 682 allssnlgerqlvhlvkvkwalpgfrlnhvdqdmavioyswmglmvfmgwrstfnvn 741
 QY 763 SRMLYEAPDLVFNRYMHSRMYSQCVRMHLSQEFGLWLOITPQELCMKALLFIIPV 822
 Db 742 srmllyepdlvfnrymhksrmysqcvrmhlsqefglwloitpqelcmkallfisiipv 801
 QY 823 DGLKNQFFDELRMNYIKELDRIIACKRNKPTSCSRFFYQTLTKLLDSVQPIARELHQFTF 882

Db 802 dglnqkffdelrmnyikeldrilackrkntscsrrfygltkildsvqpiarelhqftf 861
 QY 883 DLLTKSHMVSVDFFPMMAEIIISVQVPKILSGKVKPPIYFHTQ 923
 Db 862 dlltkshmvsvdfpemmaeiliisvqvpkilsqkvpkiyfhqtg 902

RESULT 8

AAP93110
 ID AAP93110 standard; protein; 902 AA.
 XX
 AC AAP93110;
 XX

DT 19-MAR-1990 (first entry)

DE Rat androgen receptor.

KW Rat androgen receptor; monoclonal antibody; ployclonal antibody; cancer.

XX Rattus rattus.

XX W08909791-A.
 XX
 XX 19-OCT-1989.
 XX

XX 13-APR-1989; 89WO-US01548.
 XX
 XX 14-APR-1988; 88US-0182646.
 XX

XX (UNIVERSITY OF NORTH CAROLINA.
 XX
 XX French PS, Wilson EM, Joseph DR, Lubahn DB;
 XX
 XX WPI; 1989-324206/44.
 XX
 XX N-PSDB; AAN91773.

PT DNA encoding androgen receptor protein - useful for transforming
 PT eukaryotic hosts for protein expression and subsequent antibody prodn.
 XX
 PS Disclosure; Fig. 5; 41pp; English.

CC Androgen receptor protein (AR) is used to produce mono- or poly-clonal
 CC antibodies. These are used for the detection and quantification of AR in
 CC the presence of endogenous androgen, as androgen will not interfere with
 CC binding. They may be used in assays to determine and quantify cellular
 CC distribution of AR in tumour tissue, and are esp. useful for evaluating
 CC prostate cancers to determine responsiveness to androgen withdrawal
 CC therapy.

XX Sequence 902 AA;

Query Match

Best Local Similarity 85.5%; Score 4200.5; DB 10; Length 902;

Matches 796; Conservative 36; Mismatches 52; Indels 57; Gaps 4;

QY 1 MEVOLGLGRVYPRPSPKTYRGAFQNLFGSVREVIONPGPRHPEAASAPPASLLLLQQQ 60

Db 1 mevhlglgrvyrppsktyrgafqnlfgsvreaiqnpgrhpeaasiappgacl-----54

QY 61 QQQ 119

Db 55 -----qqrqetprrrrrqhpqdgspqahirgttgylaleeqgqs 96

QY 120 QPQSALECHPERGCVPEFGAAVAASKGLPQQLPAPDEDDSAAPSTLSLLGPTFPGLSSC 179

Db 97 qqgsaseghpesgcipegaatapgkglpqppappdgdasaapstlsllgptfpglssc 156

QY 180 SADLKDILSEASTMOLL-----QQQQQEAIVSESSSGRAREAGAPTS 222

Db 157 sadikdlilseagtmllqq 216

Db 562 ckvffkraegkqylcasrndetldkfrkncpsclrkcyegntlgarklklgnlk 621
 QY 643 LOEGEASSTSTTEETOKLTVSHIEGYECQPIFLNVLAEIEPGVVCAGHNNQDPSFA 702
 Db 622 lqegengsagspteqskmtvshiegyecqpfllnvleapgvvcaghdnnpdafa 681
 QY 703 ALLSSNEIGEROLVHVVKWAKALPGFRNLHVDDQMAVIOYSWMGLMVFMAGWRGFTNNV 762
 Db 682 allssinelgerqlvkvkwalpgrnlhvddqmvavieswmglmvfmagwrsftnvn 741
 QY 763 SRMLYFAPDLVFNEMRHSRMYSQCVRMHLSQBFGLQITPQBFCLMKALLLSIIPV 822
 Db 742 srmlfapdlvfnemrhmksrmysqcvrmhlsqbfglqitpgefclmkalllsiiipv 801
 QY 823 DGLKNOFFDELRMNYIKELDRIAACKRNPTSCSRFFVQLTKLDSVQPIARELHQFTF 882
 Db 802 dglknkffdelrmnyikeldrriackrnptscsrffvqltklidsvqpiarelhqftf 861
 QY 883 DLLIKSHMVSVDPEMMAEIIISVQVPKILSGVKPIYFHTQ 923
 Db 862 dllikshmsvdpemmaeiiisvqvpkllsgkvkpiyfhtq 902

RESULT 10

AAY21627
 ID AAY21627 standard; protein; 452 AA.

XX AC AAY21627;

XX DT 11-AUG-1999 (first entry)

XX DE Ligand binding domain of nuclear receptor hAR.

XX KW Thyroid hormone receptor; aromatic compound; ligand binding domain;
 KW alpha-glucosylphosphate dehydrogenase; cardiac; obesity; triglyceride;
 KW plasma cholesterol; anti-hypertriglyceridaemic; atherosclerosis; GPDH;
 KW thyroid hormone replacement therapy; nuclear receptor.

XX OS Homo sapiens.

XX PA WO9926966-A2.

XX PD 03-JUN-1999.

XX PF 25-NOV-1998; 98WO-US25296.

XX PR 26-NOV-1997; 97US-0980115.

XX PA (RBEG-) UNLV CALIFORNIA.

XX PI Aprilletti JW, Baxter JD, Fletterick RJ, Kushner PJ;

XX PI Scanlan TS, Shiau AK, Wagner RL, West BL;

XX DR WPI; 1999-357810/30.

XX PT Modulating activity of a thyroid hormone receptor

XX PS Disclosure; Fig 3H-R; 447pp; English.

XX CC The invention relates to a method for modulating activity of a thyroid
 CC hormone receptor that comprises administration of an aromatic compound
 CC which fits spatially and preferentially into a thyroid hormone ligand
 CC binding domain. The aromatic compound (of a specified formula) can be
 CC used to increase alpha-glucosylphosphate dehydrogenase (GPDH) levels, at
 CC levels which do not significantly modify cardiac GPDH levels and are
 CC indicated in the treatment of obesity. The compound also lower total
 CC plasma cholesterol and triglyceride levels and can be used as anti-
 CC hypertriglyceridaemic agents. The compound may also be used for treating
 CC atherosclerosis and may be indicated in thyroid hormone replacement
 CC therapy in patients with compromised cardiac function. Sequences
 CC AAY21621- 636 amino acid sequences of ligand binding domains of several
 CC members of the nuclear receptor superfamily.

SQ Sequence 452 AA;

Query Match 49.5%; Score 2429; DB 20; Length 452;
 Best Local Similarity 99.8%; Pred. No. 7.9e-156;
 Matches 451; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 472 GGGGEGAGAVAPYGYTRPPQGLAGQESDFTAPDVWYVPGMVSRVYPSPTCVKSEMGPMW 531
 Db 1 ggggeagavapygytrppqglagqesdfcapdvwypgmvsrvypspcvksemgpmw 60
 QY 532 DSYSGPYGDMRELTARHVLPIDYFPQKTCICGDEASQCHYGALTCGSCVFFKRAA 591
 Db 61 dsysgpygdmrletardhvlpidyfpqktcticgdkasgchygaltcgscvffkraa 120
 QY 592 EGKOKYLCASRNDCTIDKFRKKNCPSCRLRKCYEAGMTLGARKLKLGNLKLQEEGEASS 651
 Db 121 egkkylicasrndctidkfrkncpsclrkcyegmtlgarklklgnlklqeegeass 180
 QY 652 TTSPTTEETOKLTVSHIEGYECQPIFLNVLAEIEPGVVCAGHNNQDPSAALLSSNEL 711
 Db 181 ttspteettokltvshiegyecqpfllnvleapgvvcaghdnnpdsfaallssinel 240
 QY 712 GEROLVHVVKWAKALPGFRNLHVDDQMAVIOYSWMGLMVFMAGWRGFTNNVSMLYFAPD 771
 Db 241 gerqlvkvkwalpgrnlhvddqmvavieswmglmvfmagwrsftnvnsmlyfapd 300
 QY 772 LVFNEMRHSRMYSQCVRMHLSQBFGLQITPQBFCLMKALLLSIIPV 831
 Db 301 lvfnemrhmksrmysqcvrmhlsqbfglqitpgefclmkalllsiiipv 360
 QY 832 DELRMNYIKELDRIAACKRNPTSCSRFFVQLTKLDSVQPIARELHQFTDILLIKSHMV 891
 Db 361 delrmnyikeldrriackrnptscsrffvqltklidsvqpiarelhqftdillikshmv 420
 QY 892 SVDPEMMAEIIISVQVPKILSGVKPIYFHTQ 923
 Db 421 svdpemmaeiiisvqvpkllsgkvkpiyfhtq 452

RESULT 11

AAR12230

ID AAR12230 standard; Protein; 630 AA.

XX AC AAR12230;

XX DT 20-AUG-1991 (first entry)

XX DE Trpe/androgen receptor DNA-binding domain fusion protein.

XX KW androgen receptor; AR; DNA-binding protein; steroid hormone.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT Protein 1..323

XX FT Region /label= 33kd trpe protein

XX FT /label= 11 amino acid linker

XX FT /label= 29kd protein incl. AR DNA-binding domain

XX FT /label= 17 amino acid linker

XX PN WO9107423-A.

XX PD 30-MAY-1991.

XX PF 19-OCT-1990; 90WO-US06015.

XX PR 17-NOV-1989; 89US-0438775.

XX PA (ARCH-) ARCH DEV CORP.

Rattus sp.
WO200127622-AD.
19-APR-2001

000 9PWNUSYSPYGMNRETARDNVIPIDYYRPPQKTCCLICGDEASGCHYA 571

177 SSCSADLKDILSE--ASTMQLL-----QQQQQEAVS-EGSSSGRAREASG 218

177 SSCSADLKDILSE--ASTMQLL-----QQQQQEAVS-EGSSSGRAREASG 218

Db	175	ssgtaahkvlprglsparqlllpasesphwsgapvkpsqaaaveeedseseesag	234
Qy	219	APTSKDNLYGGTSTISDNKELCKAVSVSMGLG-----VEALEHLSPG	262
Db	235	pllkqkpralgaa--agggaacppgaaggvalvpkedsrfsaprvaveqadmapg	292
Qy	263	EOLRG-----DCWYAPLGV-----PPAVRPTPCA--	287
Db	293	rsplattvmdfihvipilpinhallaatrqlledesvvggagaasafapp--rtsccass	350
Qy	288	-PLAECGSLDDSGAGSTEDTAE---YSPFKGGYTKLEGEGLGCGSAAAGSSGTLE	342
Db	351	tpva--vqdfpcayppdaepkddaypysdfappalk-ikeeeegaeasarsprs----	403
Qy	343	LPSTLSLYKSGALDEAAAYOSRYNFPALAGPPPPPPPHPHARIKLENPLDYSAWA	402
Db	404	-----ylvaganpaa-----fdpfl-----gpppplpp-----	427
Qy	403	AAACQCRVGDLSLHGAGAGPGSGSPSAAASSSWH---TLTAE-----EGOLYGPCGG	454
Db	428	-ratpsrpg-----aavtaapasasvssasgstleclilykaegappggfapppek	481
Qy	455	GGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWPGGMVSR	514
Db	482	apgascllprdgllpstsasaaaga-apaly--palgng-----lpqlgyqaavlk	532
Qy	515	-VPYSPFCVKSEMPWMSYSGPYGDMRLETARDHVLPIDYFP--PQKTCILCGDEAS	571
Db	533	glpqvypyl-nylrpdseasqsp-----qysfeslpqkiclicgdeas	575
Qy	572	GCHYGALTCGCKVFFKRAAGKOKYLCAASNDCITDKFRKNCPSRLKRCYEAAGMTLG	631
Db	576	gchysvltcgscvfkframeqghnycagrndcivdkirrkncpacrlkccqagmvlg	635
Qy	632	ARKLKLGNLKLQEGEASSTSP-----TEETTQKLTVSHIEGYECQPIFLNLEAIE	685
Db	636	grkfkfkfnkvrvrvaldavalpqlgvpnseqalsqrftfpggdiqlippllnllmsie	695
Qy	686	PCVVCAGHNNQPSFAALLSLNELGELROLVHVVKAKALPGFRNLHVDODMAVIOYSW	745
Db	696	pdviyagndktptdsssltslnqlgerqlsvvkskslpgrfnhlddqlilqysw	755
Qy	746	MGLVFMAGWRSFTNVNSRMLYFAPDLVFNEMRHKSMYSQCVRMRHLSQEFWQLITP	805
Db	756	mslmwfiglwsrykhwsgmlyfapdlilneqrnkessfyslctmwqipqefvklqvsq	815
Qy	806	QBEFLCKALLFSIIPVDGLNKQFFDELMNYIKELDRITACKRKNTSCSRFFYQLTJK	865
Db	816	eeflcmkvllllntlplqlrsqtqfeemrssyirelikaglrqkgvsssqrfyqltk	875
Qy	866	LLDSVQPTARELHQFTDLLILKSHMVSDPFPMAEIIISVQVPTLSCGKVKPIYFH	921
Db	876	lidnlhivkqlhlyclntfqlrsalsvefpeemsevvaaqlpkilagmvkpllfh	931
RESULT 15			
AA97297			
ID	AA97297	standard; Protein: 933 AA.	
XX	AC	AA97297;	
XX	AC	AA97297;	
DT	03-JAN-2001	(first entry)	
XX	DE	Human progesterone receptor B-form.	
XX	KW	Recombinant DNA; gene therapy; hormone responsive element;	
KW	KW	transgene; HRE; haemophilia; clotting factor IX; vaccine;	
KW	KW	regulation; breast cancer; ovarian cancer; prostate cancer;	
KW	KW	von Willebrand disease; cystic fibrosis; hormone; receptor; human;	
XX	XX	blood.	
OS	XX	Homo sapiens.	
XX	XX		

PN	WO200049147-A1		
XX	24-AUG-2000		
PF	18-FEB-2000; 2000WO-EP01368.		
XX	19-FEB-1999; 99DE-1007099.		
PR	19-FEB-1999; 99US-0120848.		
XX	(THER-) THERAGENE BIOMEDICAL LAB GMBH.		
PA	Hauser-funke C;		
PI	WPI; 2000-549273/50.		
XX	N-PSDB; AAA53851.		
DR			
XX			
PT	Novel nucleic acid construct useful in gene therapy comprising an		
PT	hormone responsive element and transgene in which the hormone		
PT	responsive element is not functionally linked to the transgene		
XX			
PS	Disclosure; Page 92-95; 100pp; English.		
XX			
CC	New nucleic acid constructs are described which comprise an hormone		
CC	responsive element (HRE) and a transgene (T). Alternatively the		
CC	nucleic acid construct, comprises at least one HRE and a transgene;		
CC	where one of the HREs is not functionally linked to the transgene;		
CC	The constructs can be used to up-regulate or down-regulate target		
CC	genes and for the delivery of vaccines. The constructs preferably		
CC	comprise a transgene which encodes a protein which is lacking in a		
CC	variety of genetic disorders or involved in conditions related in		
CC	inappropriate responses to hormones, for example hormone-dependent		
CC	cancers such as breast, ovarian, and endometrial cancers and prostate		
CC	cancer. The transgene may also be used to replace a defective gene		
CC	resulting in such genetic disorders as haemophilia, von Willebrand		
CC	disease, and cystic fibrosis. Vectors comprising these constructs		
CC	where the transgene is human clotting factor IX can be used for		
CC	treating blood clotting disorders such as haemophilia A or B on		
CC	administration to an organism or to a cellular system. The constructs		
CC	have applications in gene therapy for treating haemophilia when the		
CC	transgene encodes a clotting factor such as clotting factor IX. The		
CC	advantage of this system is that the hormone-hormone receptor complex		
CC	contains a hormone receptor that becomes activated after binding of		
CC	its specific hormone. The hormone receptor in the activated state is		
CC	able to recognise and bind to its specific hormone responsive		
CC	element. The presence of a transgene encourages binding of a		
CC	nucleic acid carrying a transgene encourages binding of a		
CC	hormone-hormone receptor complex. Thus the activated hormone receptor		
CC	acts as a link between the nucleic acid carrying the transgene and the		
CC	hormone known to interact with the cell membrane.		
XX			
SQ	Sequence 933 AA:		
Query Match 25.6%; Score 1256; DB 21; Length 933;			
Best Local Similarity 34.5%; Pred. No. 2.5e-76;			
Matches 349; Conservative 119; Mismatches 329; Indels 214; Gaps 33;			
Qy	38	GPRHEAASAAP-----PGA-----SLLLQQQQQQQQQQ 66	
Db	8	gprhivagppspvevsgpllcraagpfgsqtsdlpevsaipisldglifprcqqg 67	
Qy	67	QOQQQQQQQQQQQQQQQQETSPRQQQQQGGEDGSPQAHRRTGYL--VLDEEQPSQPQA 124	
Db	68	dpsdektqdgqslsdvegaysraeatraggssssppekdsglldsvldtlapsgpgs 127	
Qy	125	LECHPERGCVPEPCAATAAASKG--LPQQLPAPDEDDSAAPSTLSLLGTFP-----GL 176	
Db	128	-----qpspacevtsswclfgelp-----edppaapqtrvisplmsrsgckvqd 174	
Qy	177	SSCSADLKDTLSE--ASTMOLL-----QQQQQEAASEGSSSGRRARASGA 219	
Db	175	ssgtaahkvlprglsparqlllpasesphwsgapvkpsqaaaveeedseseesag 234	

